IASO Biotherapeutics
Focused on the discovery, development and commercialization of cell therapies in the field of oncology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
IASO Biotherapeutics, founded in 2017, is a clinical-stage biopharmaceutical company specializing in the development and commercialization of cell therapies for oncological and autoimmune diseases. The company's core focus is on Chimeric Antigen Receptor (CAR)-T cell therapies, with a pipeline that includes candidates for various conditions.
A key product in their portfolio is Equecabtagene Autoleucel (also known as CT103A), a fully human BCMA CAR-T therapy for the treatment of relapsed/refractory multiple myeloma (RRMM). The company has presented data showing promising efficacy for this treatment. Beyond oncology, IASO is exploring the application of its cell therapies in autoimmune diseases, with studies underway for conditions such as multiple sclerosis (MS).
The company manages the entire lifecycle of its therapies, from initial discovery and development to manufacturing and eventual commercialization. It has received Investigational New Drug (IND) application approvals from regulatory bodies, including the FDA in the United States, allowing it to conduct clinical trials and advance its therapeutic candidates.
Keywords: cell therapy, biopharmaceutical, CAR-T, multiple myeloma, multiple sclerosis, oncology, autoimmune diseases, clinical-stage, BCMA, Equecabtagene Autoleucel